---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-053829"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:35:26.006216+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q4 net sales $74.4M, up 10.3% YoY; adjusted EBITDA $7.3M; new CEO Capper appointed

## Summary
- Q4 net sales $74.4M (+10.3% YoY); full year $267.8M (+3.6%). Highest quarterly since Q4 2019.
- Q4 net loss $0.4M vs net income $2.2M in prior year; FY net loss $30.2M vs $10.3M.
- Adjusted EBITDA Q4 $7.3M (improved from $3.6M); FY adjusted EBITDA $3.9M (from $18.7M).
- Appointed Joseph H. Capper as CEO and Director; Ricci S. Whitlow as COO.
- Commenced first registrational trial of mDHACM for knee osteoarthritis; launched EPIFIX in Japan via GUNZE.

## SEC filing metadata
- accession: 0001193125-23-053829
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000119312523053829/0001193125-23-053829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000119312523053829/d439845d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-053829
- JSON: https://secwatch.observer/filing/0001193125-23-053829.json
- Plain text: https://secwatch.observer/filing/0001193125-23-053829.txt

## Key facts
- Earnings Releases
  MIMEDX GROUP, INC. reported Full year ended December 31, 2022 results: revenue Net sales of $267.8 million for full year 2022, net income Net loss of $30.2 million for full year 2022, EPS Net (loss) income per common share - basic and diluted of ($0.33).
  - Period: Full year ended December 31, 2022
  - Revenue: Net sales of $267.8 million for full year 2022
  - Net income: Net loss of $30.2 million for full year 2022
  - EPS: Net (loss) income per common share - basic and diluted of ($0.33)
  - Result: reported results
  source text: Three Months Ended December 31, Twelve Months Ended December 31, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 74,375 $ 67,409 $ 267,841 $ 258,615 Net (loss) income (415 ) 2,215 (30,197 ) (10,285 ) EBITDA 1 2,043 4,427 (20,929 ) 125 Adjusted EBITDA 1 7,317 3,609 3,914 18,726 Net (loss) income per common share - basic $ (0.02 ) $ 0.01 $ (0.33 ) $ (0.15 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/1376339/000119312523053829/0001193125-23-053829-index.htm
- Earnings Releases
  MIMEDX GROUP, INC. reported Fourth quarter ended December 31, 2022 results: revenue Net sales of $74.4 million for fourth quarter 2022, net income Net loss of $0.4 million for fourth quarter 2022, EPS Net (loss) income per common share - basic and diluted of ($0.02).
  - Period: Fourth quarter ended December 31, 2022
  - Revenue: Net sales of $74.4 million for fourth quarter 2022
  - Net income: Net loss of $0.4 million for fourth quarter 2022
  - EPS: Net (loss) income per common share - basic and diluted of ($0.02)
  - Result: reported results
  source text: Three Months Ended December 31, Twelve Months Ended December 31, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 74,375 $ 67,409 $ 267,841 $ 258,615 Net (loss) income (415 ) 2,215 (30,197 ) (10,285 ) EBITDA 1 2,043 4,427 (20,929 ) 125 Adjusted EBITDA 1 7,317 3,609 3,914 18,726 Net (loss) income per common share - basic $ (0.02 ) $ 0.01 $ (0.33 ) $ (0.15 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/1376339/000119312523053829/0001193125-23-053829-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.